Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.

Selected Research

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Yixin Wang, The Lancet, 2-23-05

Researchers in this study hoped to use “genome-wide measures of gene expression” to “identify patterns of gene activity that [can] subclassify tumours” and hopefully provide clinicians with better ability to target specific treatments in patients with lymph-node-negative breast cancer. The researchers used Affymetrix Human U133a GeneChips, to analyze “the expression of 22,000 transcripts from total RNA of frozen tumour samples from 286 lymph-node-negative patients who had not received adjuvant systemic treatment.

They found that “in a training set of 115 tumours” they were able to identify “a 76-gene signature consisting of 60 genes for patients positive for oestrogen receptors (ER) and 16 genes for ER-negative patients. This signature showed 93% sensitivity and 48% specificity in a subsequent independent testing set of 171 lymph-node-negative patients. The gene profile was highly informative in identifying patients who developed distant metastases within 5 years…even when corrected for traditional prognostic factors in multivariate analysis. The 76-gene profile also represented a strong prognostic factor for the development of metastasis in the subgroups of 84 premenopausal patients..87 postmenopausal patients…and 79 patients with tumours of 10-20 mm…a group of patients for whom prediction of prognosis is especially difficult.”

They conclude that “the identified [gene] signature provides a powerful tool for identification of patients at high risk of distant [tumor] recurrence. The ability to identify patients who have a favourable prognosis could, after independent confirmation, allow clinicians to avoid adjuvant systemic therapy or to choose less aggressive therapeutic options.”

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000